Calciphylaxis
MONDO:0017215Calciphylaxis is a disease in which blood vessels (veins and arteries) become blocked by a build-up of calcium in the walls of the vessels, preventing blood from flowing to the skin or internal organs. The lack of blood flow (ischemia) damages healthy tissue and causes itto die (necrosis). The most obvious and frequent symptom of calciphylaxis is damage to the skin, as ulcers can developand become infected easily. Calciphylaxis can also affect fat tissue, internal organs, and skeletal muscle, causing infections, pain, and organ failure.These symptoms are often irreversible, and many individuals with calciphylaxis may not survive more thana few months after they are diagnosed due to infection that spreads throughout the body (sepsis), or organ failure. The exact cause of calciphylaxis is unknown. Treatments may include medications to reduce pain, antibiotics to treat infections, and various approaches to preventing the development or worsening of this condition.
Also known as: idiopathic calciphylaxis
8 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could an arthritis drug stop a deadly skin condition?
Disease control Not yet recruitingThis trial tests whether tocilizumab, an anti-inflammatory drug, can stop the progression of calciphylaxis—a rare condition where calcium buildup blocks skin blood vessels, causing painful, non-healing wounds. Ten adults with calciphylaxis and end-stage kidney disease will receiv…
Phase: PHASE1 • Sponsor: Boston Medical Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Oxygen chamber therapy put to the test for dozens of diseases
Disease control Not yet recruitingThis study will test hyperbaric oxygen therapy (HBOT) — breathing pure oxygen in a pressurized chamber — for over 30 conditions, including long COVID, Crohn's disease, frostbite, and multiple sclerosis. Researchers will track 100 patients to see if HBOT improves their quality of …
Phase: PHASE4 • Sponsor: Jay C. Buckey Jr. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for rare, painful skin disease: experimental drug EPN-701 enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called EPN-701 for calciphylaxis, a rare condition causing painful skin sores with no approved treatment. About 60 adults with moderate to severe pain and at least one open sore will receive the drug. The main goals are to see if EPN-701 safely reduces…
Phase: PHASE2 • Sponsor: Sagar U. Nigwekar, MD, MMSc • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC